[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@LPessa7654 personofinterest
personofinterest posts on X about $imrx, $rvmd, $15b, $imrxs the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
- X Month XXXXX +1,115%
Mentions: X #
- X Month XX +433%
Followers: XX #
- X Week XX +8%
- X Month XX +50%
CreatorRank: undefined #
Social Influence
Social topic influence $imrx #1, $rvmd #3, $15b, $imrxs #1, os, $rvmds #1, combo, $03b, $02b, strong
Top accounts mentioned or mentioned by @nachotrust @bananaoncology @aditharun @mainz058 @andreagtc @quantumup1 @houndcl @george42600360 @randombiothinks @skipperdoodle3 @aditharun_ @jonnyfunguy @broheim777 @purpledrinkllc @hypertechinvest @investingcom @kjerath @ashton1nvests @banana_oncology
Top assets mentioned Revolution Medicines, Inc. Common Stock (RVMD)
Top Social Posts
Top posts by engagements in the last XX hours
"@Banana_Oncology @aditharun_ @houndcl I believe the other question is with such an uncertain outcome if a $15b valuation of $rvmd vs $0.3b (with $0.2b in cash) of $imrx is justified"
X Link 2025-12-11T14:41Z XX followers, XXX engagements
"@aditharun_ isnt $rvmd Ph3 for 2L only my understanding was that for 1l patients only $imrx was entering Ph3"
X Link 2025-12-09T23:13Z XX followers, XXX engagements
"@aditharun_ @Banana_Oncology @houndcl Since $rvmd drug requires a KRAS mutation while $IMRX doesnt is there any reason these treatments couldnt coexist in the first-line setting"
X Link 2025-12-11T18:02Z XX followers, XXX engagements
"@Investingcom $IMRX"
X Link 2025-11-22T20:40Z XX followers, XXX engagements
"@Banana_Oncology $IMRX has a XX% OS in X months and XX% in X months in 1L PDAC with less toxicity. When they release the XX months result next quarter $rvmd will go to zero"
X Link 2025-11-24T11:16Z XX followers, XXX engagements
"@NachoTrust @Andre_AGTC @Quantumup1 $RVMD's strong mono/combo efficacy is in 2L PDAC where advanced disease makes RAS signals easier to block but 1L data remains immature & inconsistent missing the big market. $IMRX shines in 1L combo with superior survival unlocking broader potential. Hope both succeed"
X Link 2025-11-30T19:24Z XX followers, XXX engagements
"@NachoTrust @Andre_AGTC @Quantumup1 $imrx makes the most sense up front: it delivers the clearest survival benefit with combo strategies to largest markets. If disease progresses $rvmd is a logical 2L option given its activity in advanced cases but is a smaller market"
X Link 2025-11-30T20:41Z XX followers, XXX engagements
"@NachoTrust @Andre_AGTC @Quantumup1 now $RVMD's $15B valuation vs $IMRX's $0.4M is absurd not to say bizarre.IMRX crushes in 1L PDAC survival (86% OS at 9mo) while RVMD's data lags in maturity. Overhyped gap ignores IMRX's edge in durability & broader potential. Undervalued gem $IMRX #Biotech"
X Link 2025-11-30T20:50Z XX followers, XXX engagements
"@George42600360 $IMRX's XX% survival at X months dominates 1L PDAC benchmarks offering superior survival in the firt market. $RVMD excels in 2L where advanced signals easier to block but 1L data is immature years for full trials ahead. Valuation gap ($15B vs $0.5B) absurd; IMRX undervalued"
X Link 2025-11-30T21:31Z XX followers, XXX engagements
"@RandomBioThinks $IMRX's XX% survival at X months dominates 1L PDAC benchmarks offering superior survival in the first market $RVMD excels in 2L where advanced signals easier to block but 1L data is immature years for full trials ahead. Valuation gap ($15B vs $0.5m) absurd; IMRX undervalued"
X Link 2025-11-30T21:32Z XX followers, XX engagements
"@aditharun_ but still early trials while $imrx is starting phase X right"
X Link 2025-12-10T03:56Z XX followers, XXX engagements
"@aditharun_ @Banana_Oncology @houndcl doesnt seem like a winner takes all"
X Link 2025-12-11T18:05Z XX followers, XX engagements